Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (Diluted Average) (2019 - 2026)

Zentalis Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 8 years, with the latest figure at $70.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) fell 1.97% year-over-year to $70.3 million; the trailing twelve-month figure through Mar 2026 stood at $70.3 million (down 1.97% YoY), and the FY2025 full-year result was $71.9 million, up 1.11% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $70.3 million, down from $71.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $71.9 million in Q3 2025, with the low at $45.2 million in Q1 2022.
• Average Shares Outstanding (Diluted Average) over 5 years is $64.4 million, with a median of $70.6 million recorded in 2023.
• Year-over-year, Shares Outstanding (Diluted Average) surged 38.19% in 2023 and dropped 1.97% in 2026.
• Tracing ZNTL's Shares Outstanding (Diluted Average) over 5 years: stood at $52.9 million in 2022, then increased by 23.75% to $65.4 million in 2023, then climbed by 8.67% to $71.1 million in 2024, then grew by 1.11% to $71.9 million in 2025, then retreated by 2.23% to $70.3 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $70.3 million (Q1 2026), $71.9 million (Q4 2025), and $71.9 million (Q3 2025), per Business Quant data.

Peer Comparison